Perkins Capital Management Inc. Has $43,000 Stake in scPharmaceuticals Inc. (NASDAQ:SCPH)

Perkins Capital Management Inc. reduced its stake in scPharmaceuticals Inc. (NASDAQ:SCPH) by 24.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 12,200 shares of the company’s stock after selling 4,000 shares during the quarter. Perkins Capital Management Inc.’s holdings in scPharmaceuticals were worth $43,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its stake in shares of scPharmaceuticals by 20.1% in the fourth quarter. Rhumbline Advisers now owns 42,554 shares of the company’s stock worth $151,000 after buying an additional 7,112 shares during the last quarter. Rubric Capital Management LP raised its holdings in scPharmaceuticals by 35.5% in the 3rd quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock worth $21,774,000 after acquiring an additional 1,250,000 shares during the period. Sanctuary Advisors LLC acquired a new position in scPharmaceuticals during the 3rd quarter worth $75,000. XTX Topco Ltd bought a new stake in scPharmaceuticals during the third quarter valued at about $124,000. Finally, Suvretta Capital Management LLC bought a new stake in scPharmaceuticals during the third quarter valued at about $9,343,000. Institutional investors own 89.52% of the company’s stock.

Wall Street Analyst Weigh In

SCPH has been the subject of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday. Maxim Group dropped their price target on scPharmaceuticals from $20.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday.

scPharmaceuticals Stock Performance

NASDAQ:SCPH opened at $3.00 on Monday. The firm’s 50-day moving average is $3.27 and its 200-day moving average is $3.77. The company has a market cap of $150.85 million, a price-to-earnings ratio of -1.58 and a beta of 0.40. The company has a debt-to-equity ratio of 1.66, a quick ratio of 6.89 and a current ratio of 8.08. scPharmaceuticals Inc. has a 52-week low of $2.75 and a 52-week high of $5.65.

scPharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The firm had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.08 million. Equities research analysts anticipate that scPharmaceuticals Inc. will post -1.53 earnings per share for the current year.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.